Azopharma has reached an agreement to purchase Kos Pharmaceuticals' R&D facility along with assets in Hollywood, FL. Azopharma chief executive officer Phil Meeks said, "We are pleased about the addition of our new facility in Hollywood, FL, and our expanded capacity to manufacture cGMP clinical trial material. This acquisition will significantly increase our ability to support our customers and our Phase I Express process, which enables our customers to move quickly and efficiently toward clinical trials. Phase I Express includes preclinical, preformulation, formulation development, analytical R&D, QC release, stability, manufacturing, packaging and labeling of clinical supplies for Phase I, studies."
The FL facilities are cGMP compliant and FDA registered and inspected, as well as DEA approved for testing all schedules of controlled drugs and for manufacture on an as-requested basis.